Evidence map›Paper›PMID 40924001›Full record

Trial reportAntimicrobial agents and chemotherapy2025

Efficacy and

Nicole E Scangarella-Oman, Deborah L Butler, John Breton, Derrek Brown, Cara Kasapidis, Helen Millns, Chun Huang, Caroline R Perry, Amanda J Sheets, Jeremy Dennison and 1 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy andAntimicrobial agents and chemotherapy · 2025
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicole E Scangarella-OmanGSK, Collegeville, Pennsylvania, USA.ORCID 0000-0003-4211-8261
Deborah L ButlerGSK, Collegeville, Pennsylvania, USA.
John BretonGSK, Collegeville, Pennsylvania, USA.
Derrek BrownGSK, Collegeville, Pennsylvania, USA.
Cara KasapidisGSK, Collegeville, Pennsylvania, USA.
Helen MillnsGSK, Stevenage, Hertfordshire, United Kingdom.
Chun HuangGSK, Collegeville, Pennsylvania, USA.
Caroline R PerryGSK, Collegeville, Pennsylvania, USA.
Amanda J SheetsGSK, Collegeville, Pennsylvania, USA.ORCID 0000-0003-3115-5016
Jeremy DennisonGSK, London, United Kingdom.ORCID 0000-0002-0063-0614
Salim JanmohamedGSK, London, United Kingdom.

Funding

GSK - US Office of the Assistant Secretary for Preparedness and Response HHSO 100201300011C
6 · The paper itself

Abstract

Two recent Phase 3 trials demonstrated the efficacy of gepotidacin compared with nitrofurantoin to treat uncomplicated urinary tract infections (uUTIs) in females. Pretreatment urine specimens were obtained from all participants. Based on pooled trial data (treatment groups combined), central laboratory culture results identified 1,421 (45%) participants with ≥1 baseline qualifying (≥10

Indexed as

Anti-Bacterial AgentsPiperazinesUrinary Tract InfectionsAcenaphthenesAdultAgedDrug Resistance, Multiple, BacterialEscherichia coliFemaleHeterocyclic Compounds, 3-RingHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsMiddle AgedNitrofurantoinProteus mirabilisAcenaphthenesAnti-Bacterial AgentsgepotidacinHeterocyclic Compounds, 3-RingNitrofurantoinPiperazinesacute cystitisantibacterial resistanceextended-spectrum β-lactamasegepotidacinmultidrug resistantnitrofurantoinphenotypeuncomplicated urinary tract infectionuropathogen

Identifiers

PMID40924001
PMCPMC12486842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.